Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Anhye Kim"'
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionDuring the COVID-19 pandemic, novel clinical trial methods known as decentralized clinical trials (DCTs) were rapidly introduced. The attitude toward operating clinical trials and perspectives on DCTs may differ between clinical trial sit
Externí odkaz:
https://doaj.org/article/37787d49b8c0440f9647e1bb7fa0ffe4
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 882 (2024)
This study investigated the usage patterns and impact of therapeutic drug monitoring (TDM) for risperidone and paliperidone in patients diagnosed with schizophrenia, utilizing retrospective real-world data sourced from a single center’s Clinical Da
Externí odkaz:
https://doaj.org/article/0d72dffd3a9c4d17bd2565a137b807da
Autor:
Wonsuk Shin, Min Young Park, Jongwoo Kim, Jihyeon Kim, Jun Hee Nam, Jongwon Choi, A‐Young Yang, Hyounggyoon Yoo, Yil‐Seob Lee, Anhye Kim
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Abstract Bersiporocin, a potent and selective prolyl‐tRNA synthetase inhibitor, is expected to show a synergistic effect with pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis. To validate the combination therapy of bersiporo
Externí odkaz:
https://doaj.org/article/fc75a5176bac4b0dbd7b9c499397d5d1
Publikováno v:
Clinical and Experimental Emergency Medicine, Vol 9, Iss 3, Pp 246-252 (2022)
Objective Steroids are used in cases of sepsis, especially in patients experiencing septic shock. However, clinical trials to date have reported contradictory results. Different patient endotypes and variations in the type and dose of steroid may be
Externí odkaz:
https://doaj.org/article/ccad48b1058643f09d33bcf5695d1cae
Publikováno v:
Pharmaceuticals, Vol 16, Iss 10, p 1457 (2023)
Overactive bladder (OAB) is characterized by urinary urgency and increased urinary frequency, substantially affecting quality of life. Tamsulosin and mirabegron combination therapy has been studied as a safe and effective treatment option for patient
Externí odkaz:
https://doaj.org/article/7775c99af5534623ac6cd2f286c41ac4
Autor:
Byung Seok Moon, Hyun Soo Park, Jung Sunwoo, In‐Hyun Lee, Anhye Kim, Seol Ju Moon, Heechan Lee, Min Hee Son, Su Bin Kim, Sun Mi Park, Sang‐Keun Woo, Jun‐Hee Jang, Bom Sahn Kim, Jee Hyun Kim, Sang Eun Kim, Howard Lee
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1747-1755 (2021)
Abstract DHP107 is a newly developed lipid‐based oral formulation of paclitaxel. We evaluated the in vivo tissue pharmacokinetics (PKs) of DHP107 in mice and patients using positron emission tomography (PET). Radioisotope‐labeled [3H]DHP107 and [
Externí odkaz:
https://doaj.org/article/b970aa3b6187424487444aadd4d3fd3f
Publikováno v:
Pharmaceuticals, Vol 16, Iss 8, p 1141 (2023)
Fexuprazan is a potassium-competitive acid blocker approved for treating gastric-acid-related diseases. Although the effectiveness of the recent formulation fexuprazan 10 mg has been demonstrated in Phase 3 clinical trials, data on the pharmacokineti
Externí odkaz:
https://doaj.org/article/46bf3662d9cd48149636c2191303de9a
Autor:
Anhye Kim, Stephen R. Dueker, Jun Gi Hwang, Jangsoo Yoon, Sang‐Won Lee, Hye Suk Lee, Byung‐Yong Yu, Kyung‐Sang Yu, Howard Lee
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 231-238 (2021)
The absorption, metabolism, and excretion (AME) profiles of KD101, currently under clinical development to treat obesity, were assessed in humans using accelerator mass spectrometry (AMS) after a single oral administration of KD101 at 400 mg and a mi
Externí odkaz:
https://doaj.org/article/6dc99301cee243abbd363fefaae288be
Publikováno v:
npj Schizophrenia, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Cytochrome P450 2D6 (CYP2D6) is expressed at high levels in the brain and plays a considerable role in the biotransformation and neurotransmission of dopamine. This raises the question of whether CYP2D6 variations and its impact on the brain
Externí odkaz:
https://doaj.org/article/a182e146ab9149d396ce0dc94cd46434
Autor:
Lien Ngo, Jaeseong Oh, Anhye Kim, Hyun‐moon Back, Won‐ho Kang, Jung‐woo Chae, Hwi‐yeol Yun, Howard Lee
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 10, Pp 584-595 (2020)
HL2351 (hIL‐1Ra‐hyFc) is a novel recombinant protein formed by the fusion of two human interleukin‐1 receptor antagonist components into one antibody‐derived fragment crystallizable portion. Although HL2351 has a pharmacological mechanism of
Externí odkaz:
https://doaj.org/article/42fafae2b10f4a889c0303af517dd643